Eton Pharmaceuticals (ETON) Stock Forecast, Price Target & Predictions
ETON Stock Forecast
Eton Pharmaceuticals stock forecast is as follows: an average price target of $8.50 (represents a 65.05% upside from ETON’s last price of $5.15) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
ETON Price Target
The average price target for Eton Pharmaceuticals (ETON) is $8.50 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $9.00 to $8.00. This represents a potential 65.05% upside from ETON's last price of $5.15.
ETON Analyst Ratings
According to 1 Wall Street analysts, Eton Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ETON stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Eton Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 06, 2024 | Chase Knickerbocker | Craig-Hallum | $8.00 | $3.71 | 115.63% | 55.34% |
| Jul 25, 2022 | - | H.C. Wainwright | $9.00 | $2.72 | 230.88% | 74.76% |
The latest Eton Pharmaceuticals stock forecast, released on May 06, 2024 by Chase Knickerbocker from Craig-Hallum, set a price target of $8.00, which represents a 115.63% increase from the stock price at the time of the forecast ($3.71), and a 55.34% increase from ETON last price ($5.15).
Eton Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $8.00 |
| Last Closing Price | $5.15 | $5.15 | $5.15 |
| Upside/Downside | -100.00% | -100.00% | 55.34% |
In the current month, the average price target of Eton Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Eton Pharmaceuticals's last price of $5.15. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 06, 2024 | Craig-Hallum | - | Buy | Initialise |
Eton Pharmaceuticals's last stock rating was published by Craig-Hallum on May 06, 2024. The company Initialise its ETON rating from "null" to "Buy".
Eton Pharmaceuticals Financial Forecast
Eton Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $7.03M | $12.00M | $5.30M | $8.50M | $3.22M | $7.36M | $2.18M | $6.09M | $775.00K | $3.07M | $11.90M | $81.00K | $-161.00K | $20.00K | $99.00K | $459.00K | - |
| Avg Forecast | $14.90M | $13.25M | $11.60M | $10.50M | $10.39M | $9.70M | $8.80M | $7.70M | $7.70M | $6.26M | $6.50M | $4.60M | $9.10M | $3.05M | $7.80M | $7.10M | $7.56M | $3.04M | $3.83M | $12.05M | $1.04M | $1.06M | $294.33K | $1.51M | $670.33K | $777.78K |
| High Forecast | $15.21M | $13.52M | $11.84M | $10.72M | $10.60M | $9.90M | $8.98M | $7.86M | $7.86M | $6.39M | $6.63M | $4.69M | $9.29M | $3.11M | $7.80M | $7.10M | $7.56M | $3.04M | $3.83M | $12.05M | $1.04M | $1.06M | $294.33K | $1.51M | $670.33K | $933.33K |
| Low Forecast | $14.61M | $12.99M | $11.37M | $10.29M | $10.19M | $9.51M | $8.63M | $7.55M | $7.55M | $6.14M | $6.37M | $4.51M | $8.92M | $2.99M | $7.80M | $7.10M | $7.56M | $3.04M | $3.83M | $12.05M | $1.04M | $1.06M | $294.33K | $1.51M | $670.33K | $622.22K |
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.12% | 1.85% | 1.15% | 0.93% | 1.06% | 0.94% | 0.31% | 0.81% | 0.25% | 0.80% | 0.99% | 0.08% | -0.15% | 0.07% | 0.07% | 0.68% | - |
Eton Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 1 analysts is $7.70M, with a low forecast of $7.55M, and a high forecast of $7.86M. ETON's average Quarter revenue forecast represents a 9.56% increase compared to the company's last Quarter revenue of $7.03M (Sep 23).
Eton Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-548.00K | $3.88M | $-2.32M | $1.06M | $-2.73M | $-169.00K | $-4.91M | $1.45M | $-6.01M | $-1.93M | $5.52M | $-7.53M | $-6.34M | $-4.57M | $-8.89M | $-2.55M | $-3.13M |
| Avg Forecast | $-7.04M | $-6.26M | $-5.48M | $-4.96M | $-4.91M | $-4.58M | $-4.16M | $-3.64M | $-3.64M | $-2.96M | $-3.07M | $-2.17M | $-4.30M | $-4.87M | $-3.68M | $-3.07M | $-3.57M | $-1.44M | $-1.81M | $5.52M | $-492.18K | $-500.37K | $-139.03K | $-4.61M | $-316.63K | $-4.38M |
| High Forecast | $-6.90M | $-6.14M | $-5.37M | $-4.86M | $-4.81M | $-4.49M | $-4.08M | $-3.57M | $-3.57M | $-2.90M | $-3.01M | $-2.13M | $-4.21M | $-3.90M | $-3.68M | $-2.45M | $-3.57M | $-1.44M | $-1.81M | $6.62M | $-492.18K | $-500.37K | $-139.03K | $-3.69M | $-316.63K | $-3.50M |
| Low Forecast | $-7.18M | $-6.39M | $-5.59M | $-5.06M | $-5.01M | $-4.67M | $-4.24M | $-3.71M | $-3.71M | $-3.02M | $-3.13M | $-2.22M | $-4.39M | $-5.85M | $-3.68M | $-3.68M | $-3.57M | $-1.44M | $-1.81M | $4.41M | $-492.18K | $-500.37K | $-139.03K | $-5.53M | $-316.63K | $-5.25M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.19% | -1.26% | 1.07% | -0.25% | 0.56% | 0.05% | 1.60% | -0.41% | 4.18% | 1.07% | 1.00% | 15.29% | 12.67% | 32.84% | 1.93% | 8.05% | 0.71% |
0 analysts predict ETON's average Quarter EBITDA for Sep 23 to be $-2.96M, with a high of $-2.90M and a low of $-3.02M. This is -176.14% lower than Eton Pharmaceuticals's previous annual EBITDA (Jun 23) of $3.88M.
Eton Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | $-579.00K | $4.56M | $-2.91M | $912.00K | $-3.19M | $-1.78M | $-5.57M | $764.00K | $-6.09M | $-2.02M | $5.12M | $-7.69M | $-6.50M | $-4.73M | $-9.05M | $-2.70M | $-3.25M |
| Avg Forecast | $3.35M | $2.19M | $902.23K | $386.67K | $257.78K | $-128.89K | $-1.80M | $-1.80M | $-1.03M | $-2.58M | $-2.32M | $-3.61M | $257.78K | $-4.75M | $773.34K | $-3.33M | $1.29M | $-3.48M | $-3.61M | $5.12M | $-6.83M | $-6.53M | $-6.70M | $-4.69M | $-6.79M | $-4.41M |
| High Forecast | $3.44M | $2.25M | $926.44K | $397.05K | $264.70K | $-125.60K | $-1.76M | $-1.76M | $-1.00M | $-2.51M | $-2.26M | $-3.52M | $264.70K | $-3.80M | $773.34K | $-2.67M | $1.29M | $-3.48M | $-3.61M | $6.14M | $-6.83M | $-6.53M | $-6.70M | $-3.75M | $-6.79M | $-3.53M |
| Low Forecast | $3.27M | $2.14M | $879.23K | $376.81K | $251.21K | $-132.35K | $-1.85M | $-1.85M | $-1.06M | $-2.65M | $-2.38M | $-3.71M | $251.21K | $-5.69M | $773.34K | $-4.00M | $1.29M | $-3.48M | $-3.61M | $4.09M | $-6.83M | $-6.53M | $-6.70M | $-5.63M | $-6.79M | $-5.29M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.22% | -1.97% | 0.81% | 3.54% | 0.67% | -2.30% | 1.67% | 0.59% | 1.75% | 0.56% | 1.00% | 1.13% | 1.00% | 0.71% | 1.93% | 0.40% | 0.74% |
Eton Pharmaceuticals's average Quarter net income forecast for Sep 23 is $-2.58M, with a range of $-2.65M to $-2.51M. ETON's average Quarter net income forecast represents a -156.54% decrease compared to the company's last Quarter net income of $4.56M (Jun 23).
Eton Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | $4.34M | $4.67M | $5.34M | $4.35M | $4.17M | $5.26M | $4.93M | $3.82M | $3.33M | $3.27M | $4.06M | $3.80M | $3.43M | $2.92M | $2.61M | $2.43M | $1.91M |
| Avg Forecast | $1.00B | $893.55M | $782.28M | $708.10M | $700.71M | $653.84M | $593.45M | $519.27M | $519.27M | $422.09M | $438.35M | $310.21M | $613.69M | $2.59M | $526.02M | $3.08M | $510.03M | $205.08M | $258.42M | $4.06M | $70.27M | $71.44M | $19.85M | $1.35M | $45.21M | $52.45M |
| High Forecast | $1.03B | $912.00M | $798.43M | $722.71M | $715.18M | $667.34M | $605.70M | $529.99M | $529.99M | $430.81M | $447.39M | $316.62M | $626.35M | $3.11M | $526.02M | $3.70M | $510.03M | $205.08M | $258.42M | $4.87M | $70.27M | $71.44M | $19.85M | $1.62M | $45.21M | $62.94M |
| Low Forecast | $985.12M | $876.03M | $766.94M | $694.21M | $686.97M | $641.02M | $581.82M | $509.09M | $509.09M | $413.82M | $429.75M | $304.13M | $601.65M | $2.07M | $526.02M | $2.46M | $510.03M | $205.08M | $258.42M | $3.25M | $70.27M | $71.44M | $19.85M | $1.08M | $45.21M | $41.96M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.01% | 0.01% | 0.02% | 0.01% | 1.61% | 0.01% | 1.60% | 0.01% | 0.02% | 0.01% | 1.00% | 0.05% | 0.05% | 0.15% | 1.93% | 0.05% | 0.04% |
Eton Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $519.27M, based on 1 Wall Street analysts, with a range of $509.09M to $529.99M. The forecast indicates a 11875.84% rise compared to ETON last annual SG&A of $4.34M (Sep 23).
Eton Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.02 | $0.18 | $-0.11 | $0.04 | $-0.13 | $-0.07 | $-0.22 | $0.03 | $-0.24 | $-0.08 | $0.21 | $-0.32 | $-0.31 | $-0.23 | $-0.50 | $-0.15 | $-0.18 |
| Avg Forecast | $0.13 | $0.09 | $0.04 | $0.01 | $0.01 | $-0.01 | $-0.07 | $-0.07 | $-0.04 | $-0.10 | $-0.09 | $-0.14 | $0.01 | $-0.15 | $0.03 | $-0.08 | $0.05 | $-0.14 | $-0.14 | $0.19 | $-0.27 | $-0.25 | $-0.26 | $-0.22 | $-0.26 | $-0.28 |
| High Forecast | $0.13 | $0.09 | $0.04 | $0.02 | $0.01 | $-0.00 | $-0.07 | $-0.07 | $-0.04 | $-0.10 | $-0.09 | $-0.14 | $0.01 | $-0.15 | $0.03 | $-0.08 | $0.05 | $-0.14 | $-0.14 | $0.19 | $-0.27 | $-0.25 | $-0.26 | $-0.22 | $-0.26 | $-0.28 |
| Low Forecast | $0.13 | $0.08 | $0.03 | $0.01 | $0.01 | $-0.01 | $-0.07 | $-0.07 | $-0.04 | $-0.10 | $-0.09 | $-0.14 | $0.01 | $-0.15 | $0.03 | $-0.08 | $0.05 | $-0.14 | $-0.14 | $0.19 | $-0.27 | $-0.25 | $-0.26 | $-0.22 | $-0.26 | $-0.28 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.22% | -2.00% | 0.79% | 4.00% | 0.87% | -2.36% | 2.75% | 0.60% | 1.78% | 0.57% | 1.11% | 1.21% | 1.22% | 0.88% | 2.24% | 0.57% | 0.65% |
According to 0 Wall Street analysts, Eton Pharmaceuticals's projected average Quarter EPS for Sep 23 is $-0.10, with a low estimate of $-0.10 and a high estimate of $-0.10. This represents a -155.56% decrease compared to ETON previous annual EPS of $0.18 (Jun 23).
Eton Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| GOSS | Gossamer Bio | $0.92 | $3.75 | 307.61% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| NUVB | Nuvation Bio | $3.05 | $7.00 | 129.51% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| CELC | Celcuity | $14.98 | $31.50 | 110.28% | Buy |
| TARS | Tarsus Pharmaceuticals | $33.26 | $61.00 | 83.40% | Buy |
| LYRA | Lyra Therapeutics | $0.28 | $0.50 | 78.57% | Hold |
| ALDX | Aldeyra Therapeutics | $6.03 | $10.00 | 65.84% | Buy |
| ETON | Eton Pharmaceuticals | $5.15 | $8.50 | 65.05% | Buy |
| TVTX | Travere Therapeutics | $13.48 | $21.60 | 60.24% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| ELVN | Enliven Therapeutics | $22.32 | $33.00 | 47.85% | Buy |
| CNTB | Connect Biopharma | $1.23 | $1.50 | 21.95% | Buy |
ETON Forecast FAQ
Is Eton Pharmaceuticals a good buy?
Yes, according to 1 Wall Street analysts, Eton Pharmaceuticals (ETON) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of ETON's total ratings.
What is ETON's price target?
Eton Pharmaceuticals (ETON) average price target is $8.5 with a range of $8 to $9, implying a 65.05% from its last price of $5.15. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Eton Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for ETON stock, the company can go up by 65.05% (from the last price of $5.15 to the average price target of $8.5), up by 74.76% based on the highest stock price target, and up by 55.34% based on the lowest stock price target.
Can Eton Pharmaceuticals stock reach $8?
ETON's average twelve months analyst stock price target of $8.5 supports the claim that Eton Pharmaceuticals can reach $8 in the near future.
What are Eton Pharmaceuticals's analysts' financial forecasts?
Eton Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $36.59M (high $37.34M, low $35.87M), average EBITDA is $-17.281M (high $-16.942M, low $-17.638M), average net income is $-3.48M (high $-3.378M, low $-3.587M), average SG&A $2.47B (high $2.52B, low $2.42B), and average EPS is $-0.135 (high $-0.131, low $-0.139). ETON's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $50.25M (high $51.29M, low $49.26M), average EBITDA is $-23.735M (high $-23.27M, low $-24.225M), average net income is $6.83M (high $7.01M, low $6.66M), average SG&A $3.39B (high $3.46B, low $3.32B), and average EPS is $0.265 (high $0.272, low $0.258).
Did the ETON's actual financial results beat the analysts' financial forecasts?
Based on Eton Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $21.25M, which missed the average analysts forecast of $27.05M by -21.44%. Apple's EBITDA was $-6.486M, missing the average prediction of $-15.92M by -59.26%. The company's net income was $-9.782M, beating the average estimation of $-7.045M by 38.85%. Apple's SG&A was $18.58M, missing the average forecast of $1.15B by -98.38%. Lastly, the company's EPS was $-0.39, beating the average prediction of $-0.19 by 105.26%. In terms of the last quarterly report (Sep 2023), Eton Pharmaceuticals's revenue was $7.03M, beating the average analysts' forecast of $6.26M by 12.29%. The company's EBITDA was $-548K, missing the average prediction of $-2.956M by -81.46%. Eton Pharmaceuticals's net income was $-579K, missing the average estimation of $-2.578M by -77.54%. The company's SG&A was $4.34M, missing the average forecast of $422.09M by -98.97%. Lastly, the company's EPS was $-0.0225, missing the average prediction of $-0.1 by -77.50%